Skip to main content
SpringerLink
Log in

Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Hormone replacement therapy is the optimal therapeutic choice for postmenopausal syndrome. While low doses of estrogens (0.3 mg/day of conjugated estrogens) can counteract neurovegetative menopausal symptoms, higher doses (0.625 mg/day of conjugated estrogens) are required to prevent bone loss in postmenopausal women. Experimental and clinical studies have shown that ipriflavone, a non-hormonal isoflavone derivative, is effective in the prevention and treatment of postmenopausal osteoporosis. The aim of the present investigation was to evaluate the efficacy and toler-ability of ipriflavone and very low doses of equine conjugated estrogens on bone loss in early postmenopausal women. Eighty-three healthy postmenopausal women (50.3±0.7 years) were enrolled for this 1-year multicenter study. All subjects were randomly allocated to receive: double placebo (n=24; group A), placebo plus conjugated equine estrogens 0.30 mg/day (n=31; group B) or conjugated equine estrogens 0.30 mg/day plus oral ipriflavone 200 mg tris in die at meals (n=28; group C), according to a double-masked design. Among women who completed the treatment period (valid completers), those of group A showed a progressive decrease in forearm bone density (FBD; measured by dual photon absorptiometry) that reached 1.7% after 12 months. The women in group B maintained their FBD in the first 6 months of treatment but, at the end of the study, showed a bone loss of 1.4% compared with basal values. By contrast, women in group C showed a significant increase in FBD after 1 year of treatment (+5.6%;p<0.01). Bothvalid completers andintention to treat analyses revealed a significant difference (p<0.05) between group A and group C over the study period. None of the treatments produced significant changes of biochemical markers of bone turnover, while hot flushes and other climacteric symptoms were significantly reduced after the sixth month of treatment in women receiving estrogens. Adverse events were generally mild, and did not differ among the groups. The results of this study suggest that low doses of estrogens combined with ipriflavone could represent a new therapeutic approach to the treatment of the postmenopausal syndrome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Recker RR. Current therapy for osteoporosis. J Clin Endocrinol Metab 1993;76:14–6.

    Google Scholar 

  2. Whittington R, Faulds D. Hormone replacement therapy. I. A pharmacoeconomic appraisal of its therapeutic use in menopausal symptoms and urogenital estrogen-deficiency. Pharmaco-Economics 1994;5:419–45.

    Google Scholar 

  3. Naessén T, Persson I, Ljunghall S, Bergstrom R. Women with climacteric symptoms: a target group for prevention of rapid bone loss and osteoporosis. Osteoporosis Int 1992;2:225–31.

    Google Scholar 

  4. Felson DT, Zhang Y, Hannan MT, et al. The effect of postmeno-pausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329:1141–6.

    Google Scholar 

  5. Field CS, Ory SJ, Wahner HW, et al. Preventive effect of transdermal 17-beta estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. Am J Obstet Gynecol 1993;168:114–21.

    Google Scholar 

  6. Stevenson JC, Cust MP, Gangar KF, et al. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 1990;335:265–9.

    Google Scholar 

  7. Whithead MJ, Townsend PT, Pryse-Davies J, Ryder TA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Engl J Med 1981;305:599–604.

    Google Scholar 

  8. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759–63.

    Google Scholar 

  9. Daly E, Roche M, Barlow D, et al. HRT: an analysis of benefits, risks and costs. Br Med Bull 1992;48:368–400.

    Google Scholar 

  10. Roche M, Vessey M. Hormone replacement therapy in the menopause: risks, benefits and costs. In Drife JO, Studd JWW, editors. HRT and osteoporosis. Berlin: Springer, 1990:363–72.

    Google Scholar 

  11. Yamazaki I. Effect of ipriflavone in the response of uterus and thyroid to estrogen. Life Sci 1986;38:757–64.

    Google Scholar 

  12. Melis GB, Paoletti AM, Cagnacci A, et al. Lack of any estrogenic effect of ipriflavone in postmenopausal women. J Endocrinol Invest 1992;15:755–61.

    Google Scholar 

  13. Yamazaki I, Kinoshita M. Calcitonin secretory property of ipriflavone in the presence of estrogen. Life Sci 1986;38:1535–41.

    Google Scholar 

  14. Agnusdei D, Adami S, Cervetti R, et al. Effects of ipriflavone on bone mass and calcium metabolism in postmenopausal osteoporosis. Bone Miner 1992;19:S43–8.

    Google Scholar 

  15. Valente M, Bufalino L, Castiglione GN, et al. Effects of 1-year treatment with ipriflavone on bone in postmenopausal women with low bone mass. Calcif Tissue Int 1994;54:377–80.

    Google Scholar 

  16. Gillings D, Kock G. The application of the principle of intention to treat analysis of clinical trials. Drug Inform J 1991;25:441–4.

    Google Scholar 

  17. Matthews JNS, Altman DG, Campbell MJ, Roystone P. Analysis of serial measurements in medical research. BMJ 1990;300:230–5.

    Google Scholar 

  18. Stevenson JC, Banks LM, Spinks TJ. Regional and total skeletal measurements in the early postmenopause. J Clin Invest 1987;80:258–62.

    Google Scholar 

  19. Gambacciani M, Spinetti A, Cappagli B, et al. Effects of ipriflavone administration on bone mass and metabolism and ovarìectomìzed women. J Endocrinol Invest 1993;16:333–7.

    Google Scholar 

  20. Reginster JY. Ipriflavone: pharmacological properties and usefulness in postmenopausal osteoporosis. Bone Miner 1993;23:223–32.

    Google Scholar 

  21. Cheng Su-Ling, Zhang Shu-Fang, Nelson TL, Warlow PM, Civitelli R. Stimulation of human osteoblast differentiation and function by ipriflavone and its metabolites. Calcif Tissue Int 1994;55:356–62.

    Google Scholar 

  22. Petilli M, Frediani U, Benvenuti S, Bianchi S, Brandi ML. Lack of stereospecific interactions between ipriflavone and the estrogen receptor. In: Riis BJ, Christiansen C, editors. Osteoporosis 1993. Copenhagen: Osteopress ApS, 1993:244–5.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Department, Chiesi Farmaceutici SpA, Parma, Italy

    L. Bufalino

  2. Institute of Internal Medicine and Medical Pathology, University of Siena, Nuovo Policlinico, Viale Bracci, I-53100, Siena, Italy

    D. Agnusdei & C. Gennari

Authors
  1. D. Agnusdei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Gennari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Bufalino
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Agnusdei, D., Gennari, C. & Bufalino, L. Prevention of early postmenopausal bone loss using low doses of conjugated estrogens and the non-hormonal, bone-active drug ipriflavone. Osteoporosis Int 5, 462–466 (1995). https://doi.org/10.1007/BF01626609

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01626609

Keywords

Search

Navigation